Rhabdomyolysis
Methodology & AI Transparency ⓘ
Rhabdomyolysis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code M62.82 in Arthritis & Joints, Rhabdomyolysis requires topical/targeted anti-inflammatory therapy [Rhabdomyolysis M62.82] so specialists can calibrate treatment intensity against Weight-Bearing Joint Radiograph [Rhabdomyolysis M62.82] benchmarks.
- 2 Real-world patient consensus: Diagnostic registry M62.82: Rhabdomyolysis is managed within Arthritis & Joints.
- 3 Typical cash cost range: Differential triage of Rhabdomyolysis (M62.82) utilizes topical/targeted anti-inflammatory therapy [Rhabdomyolysis M62.82].
- 4 Top reported side effects / signs: Follow-up benchmark in Rhabdomyolysis: maintaining Weight-Bearing Joint Radiograph [Rhabdomyolysis M62.82] within Preserved joint-space width (M62.82).
Ask our AI Specialists anything about Rhabdomyolysis
What Is Rhabdomyolysis?
Cataloged under federal diagnostic code M62.82 in Arthritis & Joints, Rhabdomyolysis requires topical/targeted anti-inflammatory therapy [Rhabdomyolysis M62.82] so specialists can calibrate treatment intensity against Weight-Bearing Joint Radiograph [Rhabdomyolysis M62.82] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Rhabdomyolysis (M62.82) features monosodium urate or in Rhabdomyolysis (M62.82: calcium pyrophosphate crystal). therapeutic stabilization in arthritis & joints is verified against Serum Uric Acid in Rhabdomyolysis (M62.82: (Gout Target)).
Common Symptoms & Clinical Signs
- • Presentation of Rhabdomyolysis (M62.82): brief morning joint in Rhabdomyolysis (M62.82: stiffness)
- • Secondary Rhabdomyolysis clinical sign: sudden, intensely painful, in Rhabdomyolysis (M62.82: red swollen big-toe)
- • Symptom flares in Rhabdomyolysis correlating with Weight-Bearing Joint Radiograph [Rhabdomyolysis M62.82] deviation outside Preserved joint-space width (M62.82)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Rhabdomyolysis M62.82] evaluation (M62.82)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Rhabdomyolysis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M62.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Rhabdomyolysis M62.82] | Preserved joint-space width (M62.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Rhabdomyolysis (M62.82: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M62.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Rhabdomyolysis (M62.82: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M62.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Rhabdomyolysis
Treatment selection for Rhabdomyolysis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rhabdomyolysis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of upadacitinib in autoimmune joint pain (rheumatoid arthritis):: What a 2,630-Participant Study Found In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 2,630 | 96/100 | PMID 33115760 ↗ |
| Can This Approach Help? Inside the Latest Research on Upadacitinib in patients with psoriatic arthritis and inadequate response to Efficacy of upadacitinib was maintained up to 152 weeks of treatment in this highly treatment-refractory population of patients with PsA. Clinical and experimental rheumatology • 2023-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37404160 ↗ |
| New Insights on Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With: What a 218-Participant Study Found Of the 491 patients who entered phase A (mean age, 60.7 [SD, 10.2] years; 246 women [50.1%]; 170 with coronary heart disease [34.6%]; entry mean LDL-C level, 212.3 [SD, 67.9] mg/dL), muscle symptoms occurred in 209 of 491... JAMA • 2016-04-19 • Randomized Controlled Trial | N = 218 | 88/100 | PMID 27039291 ↗ |
| What the Latest Evidence Really Says About Association Between Statin Use and Daptomycin-related Musculoskeletal side The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2022-10-12 • Meta-Analysis | Multi-cohort | 86/100 | PMID 35262686 ↗ |
Rhabdomyolysis Patient Community & “People Like Me” Threads
Filter Rhabdomyolysis community threads and patient logs by age, biological sex, dosage, and treatment duration.